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ABSTRACT
Aims: To demonstrate the efficacy of five small molecule compounds for inhibiting the
growth of Mycobacterium tuberculosis. To present evidence that these compounds will
penetrate into the central nervous system.
Study Design: Five small molecule compounds bearing a hydrazide group were
synthesized utilizing microwave excitation. These compounds were then placed into tissue
culture with Mycobacterium tuberculosis at various concentrations for evaluation of
bacterial growth inhibition.
Place and Duration of Study: The compounds to be tested were prepared at the
University of Nebraska Chemistry Department August 2013. The evaluation of antibacterial
activity was determined at the Texas A&M Health Science Center during October to
December of 2013.
Methodology: Applying microwave excitation for generation of hydrazide groups within
the structure of small molecule carboxylic acids, five agents were prepared for evaluation
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of bacterial growth inhibition. These agents were dissolved into tissue culture media at
various concentrations.  Having various levels of tuberculostatic agents, then tuberculosis
bacteria were added to determine level of growth inhibition. Growth inhibition of the
bacteria was achieved and measured by compound concentration for comparison and
evaluation.
Results: Five compounds having a hydrazide functional group greatly inhibited the growth
of Mycobacterium tuberculosis. All five agents had molecular weight less than 215
grams/mole and polar surface area of less than 70 Angstroms2.  Values of Log P ranged
from -0.226 to 0.998.  Values of Log BB (Log [Cbrain/Cblood]) ranged from -0.711 to - 0.525,
with a range in central nervous system penetration Cbrain/Cblood of 0.195 to 0.299. All
compounds showed zero violations of the Rule of 5. Substantial inhibition of bacterial
growth was observed at concentrations as low as 30 micrograms/mL, as measured by
optical density and colony forming units.
Conclusion: These five hydrazide compounds substantially decreased the proliferation of
tuberculosis bacteria at concentrations as low as 30 micrograms/mL. In addition, their
physicochemical properties are shown to allow high levels of penetration into the central
nervous system.
Keywords: Tuberculosis; Mycobacterium tuberculosis; tuberculostatic; isoniazid.
ABBREVIATIONS
Term: SMILES, Simplified Molecular-Input Line-Entry System; TB, tuberculosis; CNS, central
nervous system; mcg, microgram; PSA, polar surface area.
1. INTRODUCTION
The causative agent for the disease referred to as tuberculosis (TB) is Mycobacterium
tuberculosis. Infections due to M. tuberculosis are still regarded as a major world-wide health
problem. Some estimates place the number of infections at approximately one-third of the
entire world’s population [1]. The World Health Organization estimates that by the year 2015
there will be as many as one billion newly infected people and as many as 200 million will
develop the active disease [1]. Approximately 2 million deaths per year are attributed to TB
and each year there can be as many as 9 million new cases [1]. As of the year 2013, it is
believed that as much as 95% of new cases and 98% of deaths attributed to TB occur in
low-income and middle-income countries [1]. The decay of health services, social-economic
decline, and emergence of drug-resistant forms of TB contribute the most to these alarming
trends [1].
An involvement of the central nervous system (CNS) will occur in up to 10% of all individuals
having TB infection [2,3]. This CNS involvement can develop tuberculoma (non-neoplastic
mass usually appearing in the lungs or brain), meningitis (inflammation of the protective
membranes covering the brain and spinal cord), abscess (area of pus that has accumulated
due to inflammation from an infection), or other form of manifestation [2]. The meningitis
form of TB is devastating and accounts for up to 5% of all extrapulmonary cases of TB [4].
Central nervous system tuberculosis infection can produce the debilitating form referred to
as tuberculosis meningitis which has a high rate of morbidity and mortality [5], this with the
infection originating in the lungs [6].
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A hematogenous (carried by the blood) proliferation of Mycobacterium tuberculosis from the
primary pulmonary infection to incur an infection of the CNS can form small subpial (beneath
the pia mater) and subependymal foci (located under the ependymal) inside the brain and
spinal cord resulting in meningitis and/or tuberculoma [7]. A TB infection of the CNS carries
a high rate of mortality and neurological morbidity [8]. In children the manifestation is usually
tubercular meningitis, post-tubercular meningitis hydrocephalus, and tuberculomas [8].
Symptoms in young children include weight loss, sleep disturbance, vomiting, and seizures;
whereas in older children it many manifest as headache, fever, vomiting, weight loss, and
photophobia [7].
Risk factors for CNS involved TB infection has been identified to include malnutrition and
recent measles infection [9].  Previous studies have shown that nearly all tuberculomas of
the brain, even irrespective of their size, can be cured by medical treatment that includes
steroids to control brain edema (accumulation of fluid) [10]. This being fortuitous due to the
fact that 40% to 66% of adults presenting TB meningitis will have extra meningeal TB
infection at the time of diagnosis [11]. Treatment of CNS tuberculosis general includes the
use of four drugs; isoniazid (INH), rifampin (RIF), pyrazinamide (PZA), and ethambutol
(EMB) [12]. Previous studies have shown that children having tuberculomas of the brain will
respond well to this four drug regimen [13]. The functional group within the molecular
structure for the first-line drug isoniazid is a hydrazide group (-C(O)NHNH2). The hydrazidegroup is the bases for the antibacterial activity expressed by the compounds synthesized
and tested in this study. Side effects to the drug isoniazid includes weakness, nausea, and
seizures [12]. One of the difficulties of diagnosis of TB meningitis is the slow develop of
symptoms that include fatigue, malaise, and fever with only the following symptoms
appearing after significant progression [14]: lethargy, unconsciousness, alterations in mental
status, vomiting/nausea, and fever.
The first-line drug isoniazid (isonicotinohydrazide) has been shown to be effective in the
treatment of TB [15].  Isoniazid is a prodrug that is activated by bacterial catalase-peroxidase
enzyme named KatG. The enzyme KatG couples the isonicotinic acyl with NADH to form
isonicotinic acyl-NADH complex that binds tightly to the enoyl-acyl carrier protein reductase
InhA, blocking the action of fatty acid synthase. This process inhibits the synthesis of mycolic
acid, required for the mycobacterial cell wall [15].
Findings of previous studies and the spread of TB world-wide clearly bespeaks for the
investigation and development of additional drugs for the treatment of CNS associated
tuberculosis.  This work presents five compounds shown to be suitable for clinical application
in the treatment of CNS associated TB infections.
2. METHODOLOGY
2.1 Reagents and Instrumentation
Chemicals and reagents were obtained from Aldrich-Sigma Company (P.O. Box 2060,
Milwaukee, WI 53201 USA).  Infrared spectroscopy can be accomplished by Mattson Galaxy
FTIR in a dimethyl sulfoxide solvent that has been dried over molecular sieves to remove
water prior to use.
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2.2 Molecular Modeling and Numerical Analysis
Molecular modeling and molecular properties were determined by utilizing ChemSketch v. 5
(90 Adelaide Street West, Toronto, Ontario M5H 3V9, Canada) and Molinspiration (Liscie
Udolie 2, SK-841 04 Bratislava, Slovak Republic). Correlation statistic by Pearson r and
other statistical analysis was accomplished by Microsoft Office Excel 2007.  Determination
for hierarchical cluster analysis was accomplished by by PAST v. 1.97(Copyright Oyvind
Hammer and Harper 1999-2010) and KyPlot version 2.0 beta 15 (copyright Koichi Yoshioka
1997 – 2001).  Toxicity assessment was accomplished by OSIRIS Property Explorer version
2 (Actelion, Gewerbestrasse 16, Ch-4123 Allschwil, Switzerland).
2.3 Bacterial Culture
2.3.1 Strain
Mycobacterium tuberculosis strain CDC1551 wild type carrying vector plasmid pJDC174
and BCG carrying the same vector expressing a codon-optimized click beetle red gene
(CBR) was used. The bacteria were grown to an optical density (OD) ~ 1.0 and then
diluted to OD = 0.5 in media for survival assays.
2.3.2 Media
M. tuberculosis were grown in Middlebrook 7H9 supplemented with albumin dextrose
complex (M-ADC) (Difco), 0.05% Tween 80 (M-ADC-Tw) and kanamycin at a final
concentration of 10µg/ml to select for plasmid maintenance in the strains.
2.3.3 Compounds
All compounds were dissolved to a final concentration of 5 mg/ml.  Both isoniazid and
compounds were sterilized by passage through 0.22 µm-syringe filters.
Survival by Optical Density:  Four clear 96-well flat bottom plates were filled with 108µl per
well of M-ADC-Tw media supplemented with 10 µg/ml kanamycin to maintain luminescence
in the strain. Each tested compound was added in duplicate wells at 72µl per well at a final
concentration of 2 mg/ml.  Similar amounts of isoniazid were added to the first two wells at a
concentration of 5 microgram/ml. Two-fold serial dilutions were carried out six times for all
compounds and isoniazid. The last row of wells was maintained without any antibiotic.  A 10
µl per well of M. tuberculosis was added to 96-well plates to give a final volume of 100µl per
well. Plates were incubated at 37ºC for 7 days and 14 days. Bacterial survival was measured
at 600 nm using an EnVision (PerkinElmer) plate reader at day 0, 2, 7 and 14 in the
presence of compounds.
2.3.4 Survival by luminescence
Four solid white 96-well flat bottom plates were prepared as before. Plates were incubated at
37ºC for 2, 7 and 14 days.  Luminescence measurements were taken for day 0, 2, 7, and 14
in the presence of tested compounds.  Bacterial luminescence was measured 5 minutes
after addition of 10µl of 5mM D-luciferin in 0.45M sodium citrate buffer pH 5.0 (Gold
Biotechnology) using a EnVision (Perkin Elmer) plate reader.  Photon collection time was
one second per well.
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2.4 Synthesis of Compounds
Prior to use the hydrazine (NH2NH2) must be distilled over CaO and NaOH.  The anhydrousNH2NH2 was collected at 113ºC and was stored sealed at -20ºC. Hydrazide derivatization:All compounds were treated similarly, place 120mg of compound into pyrex open test tube
with 64 microLiter of SOCl2. Microwave 3 to 5 minutes (avoid over-heating as that will causedegradation of the agent), allowed to cool to room temperature. Vacuum pump removal of
any unreacted thionyl chloride is recommended. Add 400 microLiter of anhydrous NH2NH2and microwave at 45 second intervals up to five minutes (avoid excess heating during
process). Excess hydrazine was removed by pump vacuum at room temperature. The
derivatives were not heated or allowed to become wet. After thorough drying they are stored
dried in air tight containers at -20ºC. The presence of the hydrazine group can be confirmed
by use of FTIR, observing for peaks at 944 cm-1 for hydrazine and 1000cm-1 to 1200cm-1 for
C-N stretch, and around 3000 cm-1 to 3500 cm-1 for N-H stretch.  Furthermore, the presence
of the hydrazide group on all final products can be confirmed by the colorimetric protocol and
UV-Visible spectrophotometric analysis utilizing Gibb’s reagent as described previously [16].
Assignments of C-13 peaks for compounds A, B, C, D, and E (ppm): (A) Aromatic carbons
C-1 134.2, C-2 136.5, C-3 129.3, C-4 131.8, C-5 125.6, C-6 127.2, 2-methyl 18.6, carbonyl
carbon 163.3; (B) Aromatic carbons C-1 130.5, C-2 127.2, C-3 129.3, C-4 141.1, C-5 129.3,
C-6 127.2; 4-methyl 20.9; carbonyl carbon 167.3; (C) Aromatic carbons C-1 135.9, C-2
129.8, C-3 129.0, C-4 127.4, C-5 129.0, C-6 129.8; α-carbon 41.5; carbonyl carbon 174.8;
(D) Aromatic carbons C-1 131.6, C-2 128.7, C-3 137.2, C-4 129.0, C-5 128.7, C-6 128.7;
carbonyl carbon 167.3; (E) Carbonyl carbon 174.1, α-carbon 36.0, β-carbon 25.3, γ-carbon
28.6, δ-carbon 33.8, ε-carbon 32.9.
3. RESULTS AND DISCUSSION
The threat to personal health that tuberculosis presents as well as its proliferation world-wide
necessitates the study and development of additional clinical therapeutics. The morbidity
and mortality of tuberculosis infection of the CNS presents unique problems even in
diagnosis, in addition to clinical treatment due to the difficulty of drugs to penetrate through
the blood-brain barrier. Here in this study are presented five small molecule compounds
showing physicochemical properties suitable for penetration into the central nervous system.
This capability requires unique and rigorous parameters for their chemical properties in
addition for the required bacterial inhibition that is specifically targeting Mycobacterium
tuberculosis.
Five small molecule compounds were synthesized applying microwave excitation to emplace
a hydrazide (-C(O)NHNH2) group to replace the initial carboxyl group (-C(O)OH). Thisfunctional group as well as other structural features lend unique physicochemical properties
suitable for passive absorption into the CNS.  Structures of compounds A, B, C, D, and E are
presented in Fig. 1. These small molecule compounds have some properties shared and
important to their efficacy to target TB infections of the CNS. Straight forward inspection
reveals the hydrazide group (-C(O)NHNH2) in position without steric hindrance inhibitingactivation by the necessary reaction to bacterial catalase-peroxidase enzyme named KatG
[15]. The hydrazide group is covalently bonded onto an aromatic ring in the case of
compounds A, B, C, and D.  However, for compound E the hydrazide group is attached to an
aliphatic chain having a terminal end bromine atom.
British Journal of Pharmaceutical Research, 4(12): 1535-1551, 2014
1540
Compound A has a methyl group (-CH3) in ortho position (the C-2 position) relative to thehydrazide group.  For compound B there is a methyl group in para position (the C-4 position)
relative to the hydrazide group. Compound C (2-phenylacetohydrazide) has an aromatic ring
with a (-CH2-) group bridging the hydrazide functional group. The compound D has achlorine atom in para position (the C-4 position) relative to the hydrazide group. Compound
E contains an aliphatic chain in place of the aromatic ring (compared to compounds A, B, C,
and D). These structural features will influence the physicochemical parameters of these
compounds.  In addition the molecular formula, elemental composition, and SMILES notation
for these five drugs are shown in Fig. 1.
Fig. 1. Molecular structures of compounds A, B, C, D, and E. The structures show the
position of the hydrazide functional group (-C(O)NHNH2), along with molecularformula, percent elemental composition, SMILES nomenclature, and IUPAC name.
Note that compounds A, B, C, and D possess an aromatic ring, while compound E
contains an aliphatic carbon group with a terminal bromine atom.  The aromatic ring
of compound B contains a methyl group (-CH3), while compound D contains achlorine atom in the para- position to the hydrazide group. These structural features
significantly affect the physicochemical properties of the compounds
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Pharmacological properties of compounds A to E are presented in Table 1. The ranges in
numerical values for Log P and molecular weight are -0.226 to 0.998 and 150.2g/mole to
209.1g/mole, respectively. The average molecular weight is 161.2g/mole with only a small
standard deviation of 25.8 g/mole (16% of the average). The polar surface area (PSA) is
constant for A through E at 55.121 A2, as is the number of oxygen atoms, nitrogen atoms,
and NHn groups. For compounds, A to E the number of oxygen and nitrogen atoms(hydrogen bond acceptors) is constant at 3. For all compounds, A to E the number of
hydroxyl groups (-OH) and number of amine groups (-NHn) (hydrogen bond donors) remainsconstant at 3. Based on the Log P values, it is observed that compounds A to E are more
lipophilic than isoniazid that has Log P equal to -0.969 (more hydrophilic), as well as having
smaller PSA values at 55.121 A2. The Pearson r correlation coefficient for Log P to the
number of atoms (r=0.6398) and molecular volume (r=0.5586) is considered strong. The
correlation for molecular volume to molecular weight is very strong at r=0.7926 and very
strong for the number of rotatable bonds to molecular weight (r=0.8733). Toxicity risk
assessment analysis showed no sizeable consideration for these five compounds having a
hydrazide functional group that is similar to the first-line drug isoniazid. Evaluation of risk
assessment for compound A showed no irritant, reproductive, or mutagenic risk.  Similarly,
compound B showed no irritant, reproductive, or mutagenic risk. For compound C, there is
no irritant or reproductive risk, with only a slight mutagenic risk. Likewise, compound D
shows no irritant, reproductive, or mutagenic risk. The outcome for compound E showed a
slight risk of irritant, reproductive, and mutagenic risk. Overall this is a supporting risk
assessment determination for all compounds A, B, C, D, and E which supports their overall
potential as tuberculostats.
As values of Log P become more positive then the level of lipophilic tendency becomes
greater. The other way around the more negative the Log P numerical value the greater the
hydrophilic tendency of the drug.  By Log P values (-0.969 for isoniazid) the first-line
tuberculostat isoniazid is the most hydrophilic of the drugs shown in Table 1.
Drug discovery is an important process of identifying potential drug candidates.  In drug
development lipophilicity and molecular weight are often increased in order to improve the
affinity and selectivity of any particular drug candidate. But this step makes it more difficult to
maintain drug-likeness optimization. Drug-likeness is a qualitative concept applied in drug
design for how drug-like a potential compound is with respect to factors like bioavailability.
Furthermore, bioavailability is a principal pharmacokinetic property of drug design involving
the absorption of the drug or the fraction of an administered dose of unchanged drug that
reaches the systemic circulation.
The Rule of five defines parameters to evaluate drug-likeness or determine if a chemical
compound having pharmacological or biological activity has properties that would make it a
likely orally active drug in humans. This set of rules states that an orally active drug has no
more than one violation of the following criteria [17]: 1) No more than 5 hydrogen bond
donors (nitrogen or oxygen atoms with one or more hydrogen atoms); 2) Not more than 10
hydrogen bond acceptors (nitrogen or oxygen atoms); 3) A molecular mass less than 500
daltons; and 4) An octanol-water partition coefficient (Log P) not greater than 5.  All five
compounds A, B, C, D, E, and isoniazid are shown to have zero violations of the Rule of 5,
which indicates favorable drug-likeness and bioavailability.
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All compounds A, B, C, D, and E were placed in bacterial culture to evaluate efficacy of
growth inhibition that is targeting Mycobacterium tuberculosis. The results show clearly that
the growth and proliferation of Mycobacterium tuberculosis are very strongly inhibited.
Results presented in Fig. 2, shows clearly the very strong inhibition of bacterial growth.
Looking at Fig. 2, it is clearly seen that significant inhibition of bacteria occurs as early as
day 2 at all concentrations of drugs (measured by OD 600nm). By day 7 the bacterial
inhibition is greater than 60% (e.g. the percent survival is at or less than 40%) for all
compounds A, B, C, D, and E at concentration of 120 microgram/mL. There is growth
inhibition greater than 60% for compounds D, E, and C at a level of 60 microgram/mL at time
day 7. By day 14 the percent bacterial growth inhibition for all drugs is greater than 80% (e.g.
percent survivial is < 20%) for all compounds A, B, C, D, and E at 60 microgram/mL
concentration and greater.  This is clearly a substantial bacterial inhibition induced by these
small-molecule compounds and at very low concentration and within a time period of seven
days.
To determine the colony-forming unit (CFU) is to obtain an estimation of viable bacterial
numbers. Unlike direct microscopic counting where all cells, whether they are dead or living
are counted; utilizing CFU counting estimates viable cells.  Evaluation of bacterial growth
inhibition for compounds A, B, C, D, and E by CFU are determined and presented in Fig. 3.
The measurement of viable bacteria (CFU) after treatment with all five compounds shows
clearly that there is a complete collapse of bacterial proliferation as early as day 2 (see Fig.
3). Furthermore, complete bacterial cell death is achieved by all five compounds by day 7
(see Fig. 3).  Likewise, by day 14 there is total bacterial cell death for all compounds A, B, C,
D, and E. This is a strong and substantial antibacterial activity that contributes to the clinical
potential of these five compounds. A very strong antibacterial action would be highly
advantageous for drugs targeting TB infections of the central nervous system.  Similarly, the
survival of bacteria was monitored by luminescence (see METHODOLOGY) and is shown in
Fig. 4. Cell number correlates with luminescent output by this assay.  Note that essentially a
complete collapse of bacterial growth is accomplished by day 2. On day 2, there was greater
than 50% cell death achieved at concentration of 30 microgram/mL and greater (i.e. survival
less than 50% by Total Flux luminescence).  This is also seen at day 7 and day 14 after
determination by luminescence.
By day 7 all compounds, A to E have induced greater than 50% cell death (bacteria cell
survival less than 50%). By day 14, the substantial level of growth inhibition is sustained and
cell death is greater than 60% at all concentration levels for all compounds A, B, C, D,
and E.
Various studies investigating the physicochemical properties of drugs known to penetrate
into the CNS, allow for determination of relevant properties that enable that action. Previous
studies have shown conclusively that small drugs penetrate through the blood-brain barrier
and into the CNS with much better efficiency [18]. Furthermore, it has been shown clearly
that drugs which strongly penetrate into the CNS will have a molecular weight of less than
400 Daltons and have PSA of less than 90 Angstroms2 [19]. Looking at Table 1 then it is
clearly seen that all drugs A, B, C, D, and E fulfil these criteria. This outcome strongly
suggests that all five of these compounds will effectively and substantially pass into the CNS
from bloodstream delivery.
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Fig. 2. Survival rate of bacteria at day 2, day 7, and day 14 when compounds A, B, C,
D, and E are dosed at different concentrations (see X-axis, concentration of drugs at
microgram/mL).  Note that by day 7, the bacterial inhibition is greater than 50% at
concentrations as low as 60 micrograms/mL for compounds C, D, and E
Other studies have found that orally active drugs targeting the CNS can be transported into
the CNS passively if they have PSA of less than 120 Angstroms2 and these drugs can be
highly effective for CNS penetration if the PSA is less than 60 to 70 Angstroms2 [20]. Again,
physicochemical properties shown in Table 1 indicate that all drugs A, B, C, D, and E having
a PSA of 55.121 A2 will strongly penetrate into the CNS to target TB bacteria.  Other studies
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have applied these molecular property parameters to design antibacterial agents for
targeting infections in the CNS: Staphylococcus aureus [21], Mycobacterium tuberculosis
[22], methicillin-resistant Staphylococcus aureus [23], and ampicillin-resistant Escherichia
coli [24].
Fig. 3. Results for bacterial inhibition by compounds A, B, C, D, and E by CFU are
shown.  Clearly there is essentially complete bacterial cell death by day 2 at all
concentrations. At day 7 and day 24 there is essentially complete bacterial cell death
at concentrations as low as 30 micrograms/mL for all compounds A, B, C, D, and E
British Journal of Pharmaceutical Research, 4(12): 1535-1551, 2014
1545
Fig. 4. Reading of luminescence of bacteria also shows drastic and effective action on bacterial
growth for each compound A, B, C, D, and E at concentrations as low as 30 microgram/mL.
Further increased inhibition of bacteria growth was achieved at greater concentrations. The cell
number correlates with luminescent output, as shown in the figure
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Table 1. Physicochemical properties of drugs
Compound Log  P Polar surface area
(Angstroms2)
Number of
atoms
Molecular
weight
(g/mole)
Number of
Oxygens &
Nitrogens
Number
of –OH
& -NHn
Violations
of rule of five
Number of
rotatable
bonds
Molecular volume
(Angstroms3)
A 0.721 55.121 11 150.2 3 3 0 1 143.28
B 0.769 55.121 11 150.2 3 3 0 1 143.27
C -0.226 55.121 11 150.2 3 3 0 2 143.52
D 0.998 55.121 11 170.6 3 3 0 1 140.25
E 0.258 55.121 10 209.1 3 3 0 5 157.20
isoniazid -0.969 68.013 10 137.1 4 3 0 1 122.56
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Earlier studies have demonstrated that the parameter of BB (Concentration in the
brain/Concentration in blood) can be accurately estimated and utilized to determine if any
perspective drug can be expected to penetrate into the CNS [25].  Study of drugs known to
effectively pierce into the CNS reveal an equation for activity prediction, that equation shown
below [25]:
Log BB = -0.0148(PSA) + 0.152(Log P) + 0.139 (1)
Applying equation (1) to values of PSA and Log P for drugs A, B, C, D, and E resulted in the
values for each, that are presented in Table 2.
Table 2. Penetration into CNS based on log bb
Compound Log BB BB = C brain/C blood
A -0.567 0.271
B -0.560 0.275
C -0.711 0.195
D -0.525 0.299
E -0.638 0.230
Isoniazid -1.02 0.0966
The average value of Log BB for all drugs in Table 2 is - 0.670 (standard deviation = 0.18)
with the minimum of - 1.02 to a maximum of - 0.525. The average value of BB for all
compounds is 0.228 (standard deviation = 0.074) with the minimum of 0.0966 and maximum
of 0.299. The Pearson r correlation of Log BB to BB is extremely strong at 0.9882. Note that
based on BB numerical values, the effective concentration of drugs A, B, C, D, and E into
the CNS are all substantially greater than that for the first-line tuberculostat isoniazid (BB =
0.0966). The level of CNS penetration increases as Log P becomes more lipophilic. This is a
powerful support for these five drugs as efficacious drugs for treatment of TB infections of
the CNS. The relationship of Log P values to numerical values of BB is shown to be linear
and presented in Fig. 5. The linear relationship of Log P to BB has a correlation of 0.9936
and coefficient of determination R2 of 0.9872. The coefficient of determination of 0.9872
indicates the relationship accounts for 98.72 % of variance in the model. This is an extremely
linear relationship with the positive correlation coefficient of 0.9936.
The purpose of cluster analysis is to discover a system of organizing observations or
objects, into groups in which members of these groups share properties in common. It is a
data reduction tool that creates subgroups that have increased manageability than the
individual datum [26,27]. The actual task of clustering has the objective of grouping a set of
objects in such a way that objects in the same group (called a cluster) are more similar (in
some sense or another) to each other than to those in other groups (clusters) [26,27].  In the
method of hierarchical cluster analysis as applied here, there is no prior knowledge as to the
number of clusters that will be produced.
Results of hierarchical clustering utilizing Euclidean distance and single linkage clustering
are shown in Fig. 6. Note that when using the physicochemical properties presented in Table
1, inclusive of isoniazid, there is a high resolution of the drugs as to the most similar.
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Fig. 5. The relationship of Log P to values of BB for these compounds is highly linear.
Note that the coefficient of determination of 0.9872 indicates that the relationship
accounts for 98.72 % of variance in the model.  Equation of the line: y = 0.0991x +
0.2022 has a correlation of 0.9936.
Fig. 6. Hierarchical cluster analysis of compounds A, B, C, D, E, and isoniazid (see
Table 1) utilizing Euclidean distance measurement and single linkage clustering
conditions
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Compounds A and B are determined to be of highest similarity and are joined at node 3.
However, the cluster of A and B are joined to compound D and C (next level of similarity) at
node 2. Further resolution appears to indicate that compound E and isoniazid are less
similar to A, B, and D; with compound C closer but distinct from those drugs.  Isoniazid
having a more negative Log P, greater PSA, and additional nitrogen atom accounts for some
difference.
The socio-economic damage evoked by tuberculosis infection across the populations are
substantial and requires alertness and methodical application of appropriate public health
measures to counter measure.  The continued study and evaluation of new tuberculostat
agents are vital due to the apparent facile nature of neurons to act as host cells for M.
tuberculosis [28] and the need for treatment improvements over mere empirical and
conventional regimens applied for pulmonary tuberculosis [29]. This study has shown that
the physicochemical properties of potential drugs can be altered to improve penetration into
the central nervous system and target very debilitating Mycobacterium tuberculosis
infections.
4. CONCLUSION
In summary, this study presents five small hydrazide-type compounds that have
physicochemical properties suitable for penetrating into the CNS. Specifically, this includes
polar surface area values of less than 60 Angstroms2. Furthermore, all five compounds show
zero violations of the Rule of 5, which indicates favorable drug-likeness and bioavailability.
Importantly, all five compounds A, B, C, D, and E inhibit growth of M. tuberculosis at
concentrations as small as 30 microgram/mL. For all five compounds and by all methods of
measurement, very substantial to complete inhibition of bacteria growth was achieved at
concentrations greater than 30 micrograms/mL. This outcome is shown by optical density
measurement at 600 nm and measurement of colony-forming units (CFU), as well as
following viable bacteria by luminescence. These trends of bacterial growth inhibition and
cell death were highly consistent when comparing OD assay, CFU assay, and cell viability
measured by luminescence.  The relationship of Log P to BB is shown to be highly linear, an
outcome suggesting a linear relationship between lipophilic tendency measured by Log P
and ability to cross into the CNS from the blood stream.  Calculation of Log BB and BB
indicates that compounds A, B, C, D, and E will have significant and even greater
penetration into the CNS than the first-line tuberculostat isoniazid. Pattern recognition
analysis indicated that compounds A and B had highest similarity, followed by D, C, and C in
order. While isoniazid was determined to be distinct from compounds A, B, C, D, and E.
That capability and the very high inhibition of Mycobacterium tuberculosis support the
potential of these agents to be effective in targeting CNS infections. A significant number of
pulmonary TB infections becomes infections of the CNS, which itself has a high morbidity
and mortality. The further investigation of novel drugs and their development will highly
benefit the clinical treatment of TB infections of the central nervous system.
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